Actinium Pharmaceuticals, Inc. - ATNM
About Gravity Analytica
Recent News
- 03.30.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03.26.2026 - 8-K/A - Current report
- 02.17.2026 - Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
- 02.13.2026 - 8-K - Current report
- 12.12.2025 - Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
- 12.01.2025 - Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
- 11.26.2025 - 8-K - Current report
- 11.14.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
- 11.05.2025 - ARS - Annual Report to Security Holders
- 11.05.2025 - DEF 14A - Definitive proxy statements